Proven/probable invasive fungal diseases (IFD) of the lung according to definition of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC/MSGERC).
Conditions
Interventions
Group 1: only antifungal therapy (100 patients): collection of material (bronchoalveolar lavage) for sequencing (NGS) and identification of the microbiome, retrospective collection of relavent data ac
Sponsors
Universitätsklinikum Freiburg, Klinik für Thoraxchirurgie
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Hemato-oncological Patients = 18 years of age at the time of the first diagnosis of blood malignancy or at the time of undergoing allogeneic hematopoietic stem cell transplantation (HSCT) 2. Treated at the Dept. for Thoracic Surgery or at the Dept. of Pediatric Hematology and Oncology from 01/2003-12/2020. 3. Proven/probable invasive fungal diseases (IFD) of the lung according to definition of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC/MSGERC).
Exclusion criteria
Exclusion criteria: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The complete remission of IFD after combined lung resection and antifungal therapy compared with antifungal therapy alone. | — |
Secondary
| Measure | Time frame |
|---|---|
| • 30-day postoperative mortality and morbidity after surgery. • Duration of antifungal therapy • Overall survival and recurrence rates of IFD Duration of antifungal therapy | — |
Countries
Germany
Contacts
Public ContactMohammed Hassan
Universitätsklinikum FreiburgKlinik für Thoraxchirurgie
Outcome results
None listed